clazakizumab formerly investigational drug aglycosylated humanized rabbit monoclonal antibody clazakizumab developed bristol myers squib alder biopharmaceuticals preliminary randomized doubleblind placebocontrolled phase doseranging study clazakizumab psoriatic arthritis patients funded manufacturer suggested clazakizumab may effective treatment option musculoskeletal aspects psoriatic arthritis however antibody lacked doseresponse immune activation dostarlimab ibalizumab httpsenwikipediaorgwikiclazakizumab